PR status is a more decisive factor in efficacy of adding pertuzumab into neoadjuvant therapy for HER2-positive and lymph node-positive breast cancer than ER status: a real-world retrospective study in China

BACKGROUND: Although neoadjuvant trastuzumab and pertuzumab (HP)-based regimens are recommended for human epidermal receptor-positive (HER2 +)/lymph node-positive (N +) breast cancer (BC) patients according to NCCN guidelines, it is undeniable that many patients achieved pathological complete respon...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xiaoyu, Liu, Zhaoyun, Li, Chao, Song, Xiang, Wang, Xinzhao, Li, Sumei, Yu, Zhiyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10506239/
https://www.ncbi.nlm.nih.gov/pubmed/37723497
http://dx.doi.org/10.1186/s12957-023-03178-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10506239/
https://www.ncbi.nlm.nih.gov/pubmed/37723497
http://dx.doi.org/10.1186/s12957-023-03178-4

Ejemplares similares